natgillin/translations-raw huggingface dataset:
Uncommon - Diabetic retinopathy Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
Ob asni – diabeti na retinopatija Dolgoro no izboljšana urejenost glikemije zmanjša tveganje za napredovanje diabeti ne retinopatije.
Skin and subcutaneous tissue disorders Uncommon - Lipodystrophy Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.
Bolezni kože in podkožja Ob asni – lipodistrofija e bolnik mest injiciranj na posameznem predelu ne menja krožno, se lahko pojavi lipodistrofija.
General disorders and administration site conditions Uncommon - Injection site reactions Injection site reactions (redness, swelling, itching, pain and haematoma at the injection site) may occur during treatment with insulin.
Splošne težave in spremembe na mestu aplikacije Ob asni – reakcije na mestu injiciranja Med zdravljenjem z insulinom se lahko pojavijo reakcije na mestu injiciranja (pordelost, oteklina, srbenje, bole ine in hematomi na mestu injiciranja).
Uncommon - Oedema Oedema may occur upon initiation of insulin therapy.
Ob asni – edemi Po za etku zdravljenja z insulinom se lahko pojavijo edemi.
Immune system disorders Uncommon - Urticaria, rash Very rare - Anaphylactic reactions Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation, reduction in blood pressure and fainting/ loss of consciousness.
Bolezni imunskega sistema Ob asni – urtikarija, izpuš aj Zelo redki – anafilakti ne reakcije Med simptomi generalizirane preob utljivosti so lahko generaliziran izpuš aj na koži, srbenje, znojenje, gastrointestinalne motnje, angionevroti ni edem, težko dihanje, palpitacije, znižanje krvnega tlaka in omedlevica/ izguba zavesti.
Generalised hypersensitivity reactions are potentially life- threatening.
Generalizirane preob utljivostne reakcije so lahko smrtno nevarne.
5 A specific overdose of insulin cannot be defined.
5 • Blage hipoglikemije je mogo e zdraviti z zaužitjem glukoze ali sladkih izdelkov.
It is therefore recommended that the diabetic patients carry some sugar lumps, sweets, biscuits or sugary fruit juice. • Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a person who has received appropriate instruction, or by glucose given intravenously by a medical professional.
Zato je priporo ljivo, da imajo diabeti ni bolniki pri sebi nekaj kock sladkorja, bonbone, piškote ali sadni sok, ki vsebuje sladkor. • Hude hipoglikemije, ko je bolnik nezavesten, je mogo e zdraviti z glukagonom (0, 5 do 1 mg), ki ga da intramuskularno ali subkutano ustrezno podu ena oseba, ali z glukozo, ki jo da intravensko zdravstveni delavec.
Upon regaining consciousness, administration of oral carbohydrate is recommended for the patient in order to prevent relapse.
Ko se bolnik zave, je priporo ljivo, da peroralno dobi ogljikove hidrate za prepre itev ponovitve.
5.1 Pharmacodynamic properties
5. 1 Farmakodinami ne lastnosti
Insulins and analogues for injection, intermediate-acting, insulin (human).
Farmakoterapevtska skupina: insulini in analogi za injiciranje, s srednje dolgim delovanjem, humani insulin.
ATC code:
ATC oznaka:
The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.
U inek insulina na znižanje glukoze v krvi je posledica lažjega privzema glukoze zaradi vezave insulina na receptorje na miši nih in maš obnih celicah in hkratne inhibicije sproš anja glukoze iz jeter.
Onset of action is within 1½ hours, reaches a maximum effect within 4-12 hours and the entire duration of action is approximately 24 hours.
Delovati za ne v 1½ ure, najve ji u inek doseže v 4– 12 urah, celotni as delovanja pa je približno 24 ur.
5.2 Pharmacokinetic properties
5. 2 Farmakokineti ne lastnosti
This process is influenced by several factors (e. g. insulin dosage, injection route and site, thickness of subcutaneous fat, type of diabetes).
Na to dogajanje vpliva ve dejavnikov (npr. odmerjanje insulina, na in in mesto injiciranja, debelina podkožnega maš evja, tip diabetesa).
Absorption The maximum plasma concentration of the insulin is reached within 2-18 hours after subcutaneous administration.
Absorpcija Najve ja koncentracija insulina v plazmi je dosežena v 2 do 18 urah po subkutani uporabi.
Distribution No profound binding to plasma proteins, except circulating insulin antibodies (if present) has been observed.
Porazdelitev Ugotovili niso nobene izrazite vezave na beljakovine v plazmi, razen na krože a protitelesa proti insulinu (e so prisotna).
Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
Izlo anje Kon ni razpolovni as je dolo en s hitrostjo absorpcije iz podkožnega tkiva.
The terminal half-life (t½) is therefore a measure of the absorption rather than of the elimination per se of
Kon ni razpolovni as (t1/ 2) je torej merilo absorpcije, ne izlo anja insulina iz plazme per se (insulin v krvnem obtoku ima t1/ 2 nekaj minut).
Trials have indicated a t½ of about 5-10 hours.
Preskušanja so pokazala t1/ 5 približno 5– 10 ur.
5.3 Preclinical safety data
5. 3 Predklini ni podatki o varnosti
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.
6 Neklini ni podatki na podlagi obi ajnih študij farmakološke varnosti, toksi nosti pri ponavljajo ih se odmerkih, genotoksi nosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja ne kažejo posebnega tveganja za ljudi.
Insulin suspensions should not be added to infusion fluids.
Suspenzij insulina se ne sme dodajati infuzijskim teko inam.
4 weeks when used or stored at room temperature (below 25°C).
6. 4 Posebna navodila za shranjevanje
Keep the vial in the outer carton in order to protect from light.
Vialo shranjujte v zunanji ovojnini za zagotovitev zaš ite pred svetlobo!
Protect from excessive heat and sunlight.
Zavarujte pred ezmerno vro ino in son no svetlobo!
10 ml glass vial (type 1) closed with a bromobutyl/ polyisoprene rubber stopper and a protective tamper-proof plastic cap.
10 ml steklena viala (steklo tipa 1), zaprta z zamaškom iz brombutil/ poliizoprenske gume in zaš itno varnostno plasti no zaporko.
7 After removing Insulatard vial from the refrigerator it is recommended to allow the vial to reach room temperature (not above 25°C) before resuspending the insulin as instructed for first time use.
Potem ko vialo insulina Insulatard vzamete iz hladilnika, jo je priporo ljivo pustiti, da doseže sobno temperaturo (do 25°C), preden insulin resuspendirate po navodilu za prvo uporabo.
Insulin suspensions should not be used if they do not appear uniformly white and cloudy after resuspension.
Suspenzij insulina se ne sme uporabiti, e po resuspendiranju niso enakomerno bele in motne.
Any unused product or waste material should be disposed of in accordance with local requirements.
7 Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
Insulatard 100 IU/ ml suspension for injection in a vial.
Insulatard 100 i. e. / ml suspenzija za injiciranje v viali
9 Dosage adjustment may be necessary when transferring patients from one insulin preparation to another (see section 4.4).
9 Prilagoditev odmerjanja utegne biti potrebna tudi, e bolniki spremenijo svojo telesno dejavnost ali obi ajno prehrano.
The needle should be kept under the skin for at least 6 seconds to make sure the entire dose is injected.
Igla mora ostati pod kožo vsaj 6 sekund, da je zagotovljeno vbrizganje celotnega odmerka.
10 A few patients who have experienced hypoglycaemic reactions after transfer from animal source insulin have reported that early warning symptoms of hypoglycaemia were less pronounced or different from those experienced with their previous insulin.
Maloštevilni bolniki, ki so po prehodu z insulina živalskega izvora doživeli hipoglikemije, so navedli, da so bili zgodnji opozorilni simptomi hipoglikemije manj izraziti ali so se razlikovali od tistih, ki so jih doživeli s prejšnjim insulinom.
Intensified control in the treatment of pregnant women with diabetes is therefore recommended throughout pregnancy and when contemplating pregnancy.
Zato je pri zdravljenju žensk z diabetesom med nose nostjo in pred nameravano nose nostjo priporo ljivo intenzivnejše nadziranje.
11 Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, naj upoštevajo ustrezne previdnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia.
11 odsotnim zaznavanjem opozorilnih znakov hipoglikemije in pri tistih, ki imajo pogoste hipoglikemije.
12 4.9 Overdose
12 • Blage hipoglikemije je mogo e zdraviti z zaužitjem glukoze ali sladkih izdelkov.
A number of cleavage (hydrolysis) sites on the human insulin molecule have been proposed; none of the metabolites formed following the cleavage are active.
Predlagana so številna mesta razcepa (hidrolize) na molekuli humanega insulina so predlagali številna mesta; nobeden od presnovkov, nastalih po razcepu, ni aktiven.
13 The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
Izlo anje Kon ni razpolovni as je dolo en s hitrostjo absorpcije iz podkožnega tkiva.
The terminal half-life (t½) is therefore a measure of the absorption rather than of the elimination per se of insulin from plasma (insulin in the blood stream has a t½ of a few minutes).
Kon ni razpolovni as (t1/ 2) je torej merilo absorpcije, ne izlo anja insulina iz plazme per se (insulin v krvnem obtoku ima t1/ 2 nekaj minut).
Trials have indicated a t½ of about 5-10 hours.
Preskušanja so pokazala t1/ 2 približno 5– 10 ur.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.
13 Neklini ni podatki na podlagi obi ajnih študij farmakološke varnosti, toksi nosti pri ponavljajo ih se odmerkih, genotoksi nosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja ne kažejo posebnega tveganja za ljudi.
30 months when stored between 2°C - 8°C.
30 mesecev pri temperaturi od 2°C do 8°C.
6 weeks when used or stored at room temperature (below 25°C).
6 tednov e bolnik uporablja zdravilo ali ga hrani pri sobni temperaturi (do 25°C).
10 ml glass vial (type 1) closed with a bromobutyl/ polyisoprene rubber stopper and a protective tamper-proof plastic cap.
10 ml steklena viala (steklo tipa 1), zaprta z brombutil/ poliizoprenskim gumijastim zamaškom in zaš itno varnostno plasti no zaporko.
14 Insulin preparations which have been frozen must not be used.
Pripravkov insulina, ki so bili zamrznjeni, se ne sme uporabiti.
After removing Insulatard vial from the refrigerator it is recommended to allow the vial to reach room temperature (not above 25°C) before resuspending the insulin as instructed for first time use.
Potem ko vialo insulina Insulatard vzamete iz hladilnika, jo je priporo ljivo pustiti, da doseže sobno temperaturo (do 25°C), preden insulin resuspendirate po navodilu za prvo uporabo.
Any unused product or waste material should be disposed of in accordance with local requirements.
14 Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
Insulatard Penfill 100 IU/ ml suspension for injection in a cartridge.
Insulatard Penfill 100 i. e. / ml suspenzija za injiciranje v injekcijskem vložku
1 cartridge contains 3 ml equivalent to 300 IU.
1 vložek vsebuje 3 ml, kar ustreza 300 i. e.
Close blood glucose monitoring is therefore recommended.
Zato je priporo ljivo je natan no nadzorovanje glukoze v krvi.
16 Dosage adjustment may be necessary when transferring patients from one insulin preparation to another (see section 4.4).
16 Prilagoditev odmerjanja utegne biti potrebna tudi, e bolniki spremenijo svojo telesno dejavnost ali obi ajno prehrano.
Injection sites should be rotated within an anatomic region in order to avoid lipodystrophy.
Mesta injiciranj znotraj anatomskega predela krožno menjavati, da bi se izognili lipodistrofiji.
The cartridges are designed to be used with Novo Nordisk delivery systems (durable devices for repeated use) and NovoFine needles.
Vložki so namenjeni za uporabo z aplikacijskimi sistemi Novo Nordisk (trajne naprave za ve kratno uporabo) in iglami NovoFine.
18 Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, naj upoštevajo ustrezne previdnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia.
18 odsotnim zaznavanjem opozorilnih znakov hipoglikemije in pri tistih, ki imajo pogoste hipoglikemije.
19 4.9 Overdose
19 Specifi nega prevelikega odmerjanja insulina ni mogo e definirati.
However, hypoglycaemia may develop over sequential stages: • Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products.
Vendar se hipoglikemija lahko razvije v dveh zaporednih stopnjah: • Blage hipoglikemije je mogo e zdraviti z zaužitjem glukoze ali sladkih izdelkov.
20 The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
Izlo anje Kon ni razpolovni as je dolo en s hitrostjo absorpcije iz podkožnega tkiva.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.
20 Neklini ni podatki na podlagi obi ajnih študij farmakološke varnosti, toksi nosti pri ponavljajo ih se odmerkih, genotoksi nosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja ne kažejo posebnega tveganja za ljudi.
6 weeks when used or carried as a spare (below 30°C).
6 tednov pri sobni temperaturi (do 30°C), e bolnik uporablja zdravilo ali ga ima pri sebi kot rezervo.
Keep the cartridge in the outer carton in order to protect from light.
Injekcijski vložek shranjujte v zunanji ovojnini za zagotovitev zaš ite pred svetlobo!
Not all pack sizes may be marketed.
Na tržiš u so lahko le nekatere velikosti pakiranj.
21 Cartridges should only be used in combination with products that are compatible with them and allow the cartridge to function safely and effectively.
Vložke se sme uporabljati samo z izdelki, s katerimi so kompatibilni in ki omogo ajo varno in u inkovito delovanje vložkov.
Insulatard Penfill is for single person use only.
Insulatard Penfill je namenjen uporabi ene same osebe.
After removing Insulatard Penfill from the refrigerator it is recommended to allow the Penfill to reach room temperature (not above 25°C) before resuspending the insulin as instructed for first time use.
21 Potem ko Insulatard Penfill vzamete iz hladilnika, je priporo ljivo Penfill pustiti, da doseže sobno temperaturo (do 25°C), preden insulin resuspendirate po navodilu za prvo uporabo.
Insulatard NovoLet 100 IU/ ml suspension for injection in a pre-filled pen.
Insulatard NovoLet 100 i. e. / ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku
23 Dosage adjustment may be necessary when transferring patients from one insulin preparation to another (see section 4.4).
23 Prilagoditev odmerjanja utegne biti potrebna tudi, e bolniki spremenijo svojo telesno dejavnost ali obi ajno prehrano.
Injection sites should be rotated within an anatomic region in order to avoid lipodystrophy.
Mesta injiciranj znotraj anatomskega predelaje treba krožno menjavati, da bi se izognili lipodistrofiji.
Insulatard NovoLet is designed to be used with NovoFine needles.
Insulatard NovoLet je namenjen za uporabo z iglami NovoFine.
NovoLet delivers 2-78 units in increments of 2 unitsThe pens should be primed before injection so that the dose selector returns to zero and a drop of insulin appears at the needle top.
Injekcijske peresnike je treba pred injiciranjem pripraviti, tako da je števil nica za nastavitev odmerka nastavljena na ni lo in se na konici igle pojavi kapljica insulina.
The dose is set by turning the selector, which returns to zero during the injection.
Odmerek se nastavi z vrtenjem števil nice, ki se med injiciranjem vrne na ni lo.
If an adjustment is needed when switching the patients to Insulatard, it may occur with the first dose or during the first several weeks or months.
Spremembe jakosti, znamke (izdelovalec), vrste (hitro -, dvojno -, dolgodelujo i insulin itd.), izvora (živalski, humani ali analogni insulin) in/ ali na ina izdelave (rekombinantna DNA ali živalski vir insulina) imajolahko za posledico spremembo odmerjanja. e je po prehodu bolnikov na Insulatard potrebna prilagoditev, je to lahko potrebno že pri prvem odmerku ali v prvih nekaj tednih ali mesecih.
24 reduce or prevent these reactions.
24 Kot pri vsakem zdravljenju z insulinom se lahko pojavijo reakcije na mestu injiciranja, med njimi bole ine, srbenje, koprivnica, oteklina in vnetje.
Oral hypoglycaemic agents (OHA), monoamine oxidase inhibitors (MAOI), non-selective beta- blocking agents, angiotensin converting enzyme (ACE) inhibitors, salicylates, alcohol, anabolic steroids and sulphonamides.
Potrebo po insulinu lahko zmanjšajo naslednje snovi: peroralni antidiabetiki zaviralci monoaminoksidaze (MAOI), neselektivni zaviralci adrenergi nih receptorjev beta, zaviralci encima angiotenzinske konvertaze (ACE), salicilati, alkohol, anabolni steroidi in sulfonamidi.
Intensified control in the treatment of pregnant women with diabetes is therefore recommended throughout pregnancy and when contemplating pregnancy.
Zato je pri zdravljenju žensk z diabetesom med nose nostjo in pred na rtovano nose nostjo priporo ljivo intenzivnejše nadziranje.
25 The patient’ s ability to concentrate and react may be impaired as a result of hypoglycaemia.
25 Hipoglikemija lahko poslabša bolnikovo zmožnost koncentracije in reagiranja.
26 Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation, reduction in blood pressure and fainting/ loss of consciousness.
Bolezni imunskega sistema Ob asni – urtikarija, izpuš aj Zelo redki – anafilakti ne reakcije Med simptomi generalizirane preob utljivosti so lahko generaliziran izpuš aj na koži, srbenje, znojenje, gastrointestinalne motnje, angionevroti ni edem, težko dihanje, palpitacije, znižanje krvnega tlaka in omedlevica/ izguba zavesti.
27 Human insulin is reported to be degraded by insulin protease or insulin-degrading enzymes and possibly protein disulfide isomerase.
Presnova Opisano je, da se humani insulin razgradi z insulinsko proteazo ali encimi za razgradnjo insulina in morda s proteinsko disulfid- izomerazo.
5.3 Preclinical safety data
27 5. 3 Predklini ni podatki o varnosti
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.
Neklini ni podatki na podlagi obi ajnih študij farmakološke varnosti, toksi nosti pri ponavljajo ih se odmerkih, genotoksi nosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja ne kažejo posebnega tveganja za ljudi.
Keep the pen cap on in order to protect from light.
Za zaš ito insulina pred svetlobo naj bo injekcijski peresnik vedno pokrit s pokrov kom.
Pre-filled pen (multidose disposable pen) comprising a pen injector with a cartridge (3 ml).
Napolnjen injekcijski peresnik (ve odmerni peresnik, ki se zavrže), ki obsega peresni injektor z vložkom (3 ml).
The cartridge is made of glass (type 1), containing a bromobutyl rubber plunger and a
Vložek je izdelan iz stekla (tipa 1), ki ima bat iz brombutilne gume in brombutil/ poliizoprenski gumijast zamašek.
28 bromobutyl/ polyisoprene rubber stopper.
V vložku je steklena kroglica, ki olajša resuspendiranje.
Pens should only be used in combination with products that are compatible with them and allow the pens to function safely and effectively.
Injekcijske peresnike se sme uporabljati samo z izdelki, s katerimi so kompatibilni in ki omogo ajo varno in u inkovito delovanje teh peresnikov.
Insulatard NovoLet is for single person use only.
28 Insulatard NovoLet je namenjen uporabi ene same osebe.
After removing Insulatard NovoLet from the refrigerator it is recommended to allow the NovoLet to reach room temperature (not above 25°C) before resuspending the insulin as instructed for first time use.
Potem ko Insulatard NovoLet vzamete iz hladilnika, je priporo ljivo NovoLet pustiti, da doseže sobno temperaturo (do 25°C), preden insulin resuspendirate po navodilu za prvo uporabo.
Insulatard InnoLet 100 IU/ ml suspension for injection in a pre-filled pen.
Insulatard InnoLet 100 i. e. / ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku
30 Dosage adjustment may be necessary when transferring patients from one insulin preparation to another (see section 4.4).
30 Prilagoditev odmerjanja utegne biti potrebna tudi, e bolniki spremenijo svojo telesno dejavnost ali obi ajno prehrano.
Insulatard InnoLet is designed to be used with NovoFine short cap needles of 8 mm or shorter in length.
Insulatard InnoLet je namenjen za uporabo z iglami NovoFine s kratkim pokrov kom, dolgimi 8 mm ali manj.
The needle box is marked with an S.
Škatla igel je ozna ena s S.
InnoLet delivers 1-50 units in increments of 1 unit.
InnoLet omogo a aplikacijo od 1 do 50 enot v korakih po 1 enoto.
The pens should be primed before injection so that the dose selector returns to zero and a drop of insulin appears at the needle top.
Injekcijske peresnike je treba pred injiciranjem pripraviti, tako da je izbirnik odmerka nastavljen na ni lo in se na konici igle pojavi kapljica insulina.
The dose is set by turning the selector, which returns to zero during the injection.
Odmerek se nastavi z vrtenjem izbirnika, ki se med injiciranjem vrne na ni lo.
If an adjustment is needed when switching the patients to Insulatard, it may occur with the first dose or during the first several weeks or months.
Spremembe jakosti, znamke (izdelovalec), vrste (hitro -, dvojno -, dolgodelujo i insulin itn.), izvora (živalski, humani ali analogni insulin) in/ ali na ina izdelave (rekombinantna DNA ali živalski vir insulina) imajo lahko za posledico spremembo odmerjanja. e je po prehodu bolnikov na Insulatard potrebna prilagoditev, je to lahko potrebno že pri prvem odmerku ali v prvih nekaj tednih ali mesecih.
31 As with any insulin therapy, injection site reactions may occur and include pain, itching, hives, swelling and inflammation.
31 Kot pri vsakem zdravljenju z insulinom se lahko pojavijo reakcije na mestu injiciranja, med njimi bole ine, srbenje, koprivnica, oteklina in vnetje.
Oral hypoglycaemic agents (OHA), monoamine oxidase inhibitors (MAOI), non-selective beta- blocking agents, angiotensin converting enzyme (ACE) inhibitors, salicylates, alcohol, anabolic steroids and sulphonamides.
Potrebo po insulinu lahko zmanjšajo naslednje snovi: peroralni antidiabetiki, zaviralci monoaminoksidaze (MAOI), neselektivni zaviralci adrenergi nih receptorjev beta, zaviralci encima angiotenzinske konvertaze (ACE), salicilati, alkohol, anabolni steroidi in sulfonamidi..
There are no restrictions on treatment of diabetes with insulin during pregnancy, as insulin does not pass the placental barrier.
Omejitev za zdravljenje diabetesa z insulinom med nose nostjo ni, ker insulin ne prehaja skozi placentno pregrado.
32 The patient’ s ability to concentrate and react may be impaired as a result of hypoglycaemia.
32 Hipoglikemija lahko poslabša bolnikovo zmožnost koncentracije in reagiranja.